Off-Label Drug Marketing

A New York federal judge has granted final approval of a $400 million settlement that ends a class action accusing Pfizer Inc. of misleading investors about illegal off-label drug marketing.... Read more

Pfizer Inc. reached a $400 million settlement in a class action brought by its investors flowing from the company’s off-label drug marketing scheme. The class action stemmed from a comprehen... Read more